Scabies is a parasitic disease of the skin that disproportionately affects disadvantaged populations. The disease causes considerable morbidity and leads to severe bacterial infection and immune-mediated disease. Scientific advances from the past 5 years suggest that scabies is amenable to population-level control, particularly through mass drug administration. In recognition of these issues, WHO added scabies to the list of neglected tropical diseases in 2017. To develop a global control programme, key operational research questions must now be addressed. Standardised approaches to diagnosis and methods for mapping are required to further understand the burden of disease. The safety of treatments for young children, including with ivermectin and moxidectin, should be investigated. Studies are needed to inform optimum implementation of mass treatment, including the threshold for intervention, target, dosing, and frequency. Frameworks for surveillance, monitoring, and evaluation of control strategies are also necessary.
Introduction
In 2017, scabies was added to the WHO list of neglected tropical diseases (NTDs). Scabies was recommended to be included as a category A NTD, defined as those conditions that fulfil all four specified criteria, and are recom mended for large-scale action in the portfolio of the NTD Department. 1 In reaching this recommendation, the WHO NTD Strategic and Technical Advisory Group noted the need for further research to inform control strategy and key issues for programmatic implementation, including ensuring affordable access to oral medications and developing guidelines for their public health use. 2 In March, 2018, the WHO NTD Global Working Group on Monitoring and Evaluation discussed scabies for the first time. 3 Key recommendations from that meeting included the need to better define the global burden, to integrate control efforts to capitalise on ivermectin-based programmes for other NTDs, and to establish interim guidelines for public health interventions for scabies control. In this rapidly evolving context, we review major advances in the science of control of human scabies from the past 5 years and identify key operational research questions that need to be addressed to develop a global scabies control programme.
The burden of scabies
Scabies is caused by infestation with the microscopic ectoparasite Sarcoptes scabiei var hominis, and leads to severe itch, skin lesions, and more serious complications due to bacterial superinfection (figure 1). Transmission requires skin-to-skin contact, and no non-human reservoir exists. Scabies occurs in all countries, but its distribution is not uniform. In high-income settings, most cases are sporadic, and the predominant public health issue is the management of outbreaks in institutions such as hospitals and residential care facilities for older people. A far greater burden of disease is found in low-income and middle-income countries, where access to effective treatment is often inadequate and population crowding increases the opportunities for transmission. Areas with hot, humid climates have the highest reported prevalence, most prominently island communities in the Pacific region and central America, and Indigenous communities of northern Australia. [4] [5] [6] In these settings, the community prevalence has been consistently estimated in the range of 20-30%, with a higher prevalence of up to 40-50% in children aged younger than 18 years (figure 2). 7, 16, 17 In other resource-poor settings where baseline prevalence is lower, change in environmental or sociopolitical conditions can be associated with scabies epidemics. 18 An example is the outbreak in the Amhara region in Ethiopia that has been in progress since 2015, and has been estimated to affect more than 1 million people. 19, 20 Circumstances associated with substantial population crowding frequently lead to high transmission, and outbreaks are common within schools, prisons, and camps for refugees and internally displaced people. 21 Scabies is one of the world's most common illnesses. The 2016 Global Burden of Disease (GBD) Study estimated the global point prevalence of scabies to be around 147 million, with 455 million annual incident cases. 22 Further GBD analyses estimated that scabies caused approximately 3·8 million disability-adjusted life-years (DALYs), ranking scabies as one of the most important NTDs. 23 Scabies causes an age-adjusted morbidity burden similar to Haemophilus influenzae, type B meningitis, and acute lymphoid leukaemia. 24 These GBD analyses are modelled on the small number of published reports on the prevalence of scabies. Of note, the disability weighting only considers the skin changes and itch directly caused by infestation. 24 The estimated burden would be far greater if the morbidity and mortality caused by the complications of scabies were included (figure 3). Scabies infestation causes a considerable proportion of bacterial skin infection (pyoderma) in many resource-poor settings, most commonly manifesting as infected sores (impetigo). 7, 16, 25, 26 For example, Aboriginal children in Australia were 12 times more likely to develop impetigo when infected with the scabies mite than where no infestation was evident, 26 and studies from Pacific island nations have estimated the attributable risk of scabies as a cause of impetigo to be 41-93%. 7,16,27 Scabetic lesions and traumatic scratching create breaches in the skin barrier that are a portal for bacterial entry. Scabies mite components such as serpins inhibit innate immune pathways including neutrophil function and directly promote the growth of Staphylococcus aureus and Streptococcus pyogenes. [28] [29] [30] [31] Skin infection due to these bacteria can lead to severe soft tissue infections and invasive disease. Infection with S pyogenes can also lead to immune-mediated complications including post streptococcal glomerulonephritis and possibly acute rheumatic fever, which in turn contribute to chronic kidney disease and rheumatic heart disease respectively (figure 3). 32, 33 Quantification of the burden of these serious health consequences attributable to scabies will give a more accurate estimate of the global burden of scabies and the potential benefit of scabies control (panel 1).
Diagnosis
Both the mapping of scabies and population-level control are hampered by the absence of a reliable, reproducible, and standardised approach to diagnosis. Two systematic reviews of diagnostic methods found inconsistency in approaches to scabies diagnosis. 34, 35 Microscopy of skin scrapings to visualise mites and eggs is highly specific but insensitive and operator dependent, and therefore generally not useful for field settings. To address this gap, an international panel of experts, convened by the International Alliance for the Control of Scabies (IACS), used a Delphi consensus method to develop the 2018 IACS Criteria for Scabies Diagnosis in research and epidemiological settings. 36 These criteria enable diagnosis and reporting in three bands of diagnostic certainty: confirmed, clinical, and suspected scabies. A diagnosis of confirmed scabies requires identification of the mite on microscopy or non-invasive visualisation techniques such as videomicrosopy and dermoscopy. 37 Clinical and suspected scabies categories rely on features of clinical history and examination. As such, the criteria can be adapted for use in a variety of settings, including field surveys, and might help to standardise reporting and the conduct of scabies research. Validation of these criteria in diverse environments is now required, followed by development of standardised training methods and materials.
Although the current focus should be on development of diagnostics for mapping and surveillance, in future, objective diagnostic tests might be needed, particularly if areas of low endemicity transition to a target of disease elimination. A point-of-care diagnostic test would be ideal for public health use. Direct skin-based testing for infestation using molecular techniques, including PCR 38, 39 and loop-mediated isothermal amplification 40 have been proposed, but none are currently ready for programmatic use. Development of ELISA-based tests to detect antibodies against scabies antigens 41 has been hindered by cross-reactivity between antigens from scabies and house dust mites. 42, 43 If a specific antibody test for scabies were developed, for it to be diagnostic, further evaluation would need to ensure that measured antibody responses were directly associated with ongoing infestation and not simply previous exposure.
In addition to molecular diagnostics, non-invasive mite visualisation methods should be further evaluated. These high-magnification methods allow direct, in-vivo visualisation of the mite (and with some methods, determination of mite survival or demise after treatment) without extraction of the mite by skin scraping. 44, 45 Although these devices are expensive and require specialised training, more simple and affordable videomicroscopes also permit accurate visualisation of the mite in vivo, and low-cost dermatoscopes have been developed. 46, 47 Further investigation and standardisation of outcome measures by use of these methods would help in assessing the efficacy of new treatments, and possibly validation of mapping and confirmation of outbreaks.
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Epidemiology and mapping
Despite an expansion of research on scabies in the past decade, the development of a global strategy has been constrained by the scarcity of prevalence data, including from those countries suspected to be at risk on the basis of routinely reported clinical data or geographical or socioeconomic characteristics. For example, a worldwide systematic review of published scabies prevalence estimates found 48 studies, of variable quality, with over-representation of countries in the Pacific region and large areas of the world having no published prevalence data. 4 Experience from other NTDs suggests that the knowledge of disease burden gained through mapping is crucial for stakeholder engagement, translational research, and successful scale-up of control programmes. 49 Given the logistic challenge and cost of detailed mapping for NTDs, 50 development of a simple, low-cost, rapid assessment tool is a priority to assist policy makers in initially showing whether scabies is likely to be a public health problem in a given context (panel 2). Standardised survey methods to map scabies prevalence would then be required for a more detailed estimate of disease burden and its variation within and between regions. Survey methods could use the 2018 IACS Diagnostic criteria, 36 if these criteria are found to be valid and reproducible. It might be possible to train non-expert examiners in a basic, brief skin examination, which could then be correlated with more detailed diagnostic methods. 51 A similar approach has been used for trachoma, in which a rapid assessment can be followed by a standardised mapping survey. [52] [53] [54] [55] Survey design will need to consider the most appropriate populations and settings in which to do mapping, including ease of access, spatial and age distributions of disease, and community acceptability. For example, mapping of children attending school could be expected to provide a representation of the groups with the highest burden in a community. This approach might be efficient, practicable, and amenable to integration with mapping for other NTDs and other health and education programmes. 56, 57 Formal comparison of school-based versus community-based sampling would help to show how well school prevalence correlates with community prevalence. 58, 59 Beyond national-level prevalence data, understanding is poor regarding the epidemiology of specific highburden areas or populations within otherwise highincome or low-prevalence settings. Recognised examples include dis advantaged Indigenous populations within Australia, New Zealand, and Canada, 26,60-62 imprisoned 63, 64 and homeless populations, 65 and groups seeking asylum within Europe. [66] [67] [68] Scabies is a disease of poverty and inequity and subpopulations with higher burdens would probably be found in many otherwise high-income settings. 69 Institutional scabies outbreaks result in considerable morbidity, stigma, and health-care cost in high-income settings. These outbreaks are typically challenging to identify and manage, leading to lengthy delays in confirmation and control, and substantial cost. [70] [71] [72] [73] Changes in social demography, particularly ageing, mean that these outbreaks might become more common, and the development of appropriate public health strategies is therefore warranted. A deeper appreciation of the features of institutional outbreaks in high-income settings could influence control of scabies elsewhere.
Transmission and complications
Despite scabies being an ancient disease, our understanding of the drivers of transmission remains poor. Understanding transmission dynamics is important for investigating the comparative effects of different control strategies, including through mathematical modelling. 74, 75 The observed cycles of scabies prevalence in some temperate settings (leading to the misnomer the 7-year itch) previously raised the possibility of herd immunity. However, in many tropical settings, recurrent infestations are common and present with more rapid onset of symptoms than in the initial infection. 43 Very high population prevalence is sustained in some of these settings, suggesting that variations across geographic regions and time are more likely to be explained by factors other than personal or herd immunity. 76, 77 Of particular importance to transmission is the role of individuals with the rare clinical variant crusted scabies (previously known as Norwegian scabies), usually in association with immunosuppression (disease-related or drug-related) or neurological illness. People with crusted scabies can carry thousands to millions of mites and are highly infectious, thereby acting as core transmitters within some communities. 78 Being unable to identify and manage these individuals might undermine the success of control programmes. 79 Understanding is incomplete as to why prevalence of crusted scabies is high in northern Australia despite the absence of identifiable causes of immunosuppression, but relatively few such cases have been described in other highprevalence settings. 16, 78, 80, 81 The pathogenic links between scabies, impetigo, the infectious complications of S aureus and S pyogenes, and the immune-mediated complications of S pyogenes need further investigation. If these high-morbidity and high-mortality conditions can be more definitively linked with scabies, and can be shown to be prevented effectively through scabies control, the rationale to invest in scabies control will be more compelling for governments, potential donors, and other stakeholders. The relevant associations have been considered most thoroughly in the Pacific region, 61, [82] [83] [84] where impetigo is very common, but scarce data from other regions suggest that endemic scabies occurs in those environments with lower prevalence of impetigo. 4 This pattern needs to be properly quantified and the reasons for any variation, if genuinely present, further explored. Impetigo caused by S pyogenes is a major cause of acute glomerulonephritis, 85 which in turn contributes to the high burden of chronic kidney disease in low-income settings. 86 Scabies has been associated with chronic kidney disease in both epidemiological studies and case reports. [87] [88] [89] Rheumatic heart disease is estimated to cause over 300 000 deaths per year, with a global distribution that overlaps with areas that are highly endemic for scabies. 90 A global resolution on rheumatic fever and rheumatic heart disease was adopted by the World Health Assembly in 2018. 91 Primary prevention of streptococcal skin infection through scabies control could potentially be an important component of preventing these diseases.
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Social and economic issues
As a disease that affects the skin, scabies is a potent cause of stigma and reduced quality of life. 9, 92, 93 Increasingly, the chronic disfigurement caused by scabies and other NTDs is understood to adversely affect mental health, 56, 94 although this aspect has not been factored into current GBD estimates of DALYs. Understanding the conception of scabies, itch, and impetigo within various cultures will help define what scabies as a public health problem means to the most affected communities. This research will also help to build partnerships with communities to develop control interventions, and to maximise participation in them. Scabies is often incorrectly attributed to poor hygiene, which can lead to stigma, shame, and reduced health seeking. However, hygiene and handwashing do not affect the mite or transmission, 95 and highly effective control has been shown without any measures addressing hygiene or environment (see section on population-level control), 96 suggesting that associations with situations of poverty and disadvantage are probably due to poor access to health care and treatment, or the effects of overcrowding. 21, 97 The economic burden of scabies in some areas is thought to be substantial, particularly due to the infestation leading to absence from employment and education, and the direct costs of accessing health care and repeated treatments (figure 3). 98 Economic studies of the costs of scabies infestation and 
Treatment
Although various effective, topical preparations exist for treatment of individual cases, for multiple reasons these agents are poorly suited to population-level control interventions. Reasons include the prolonged duration of application required and local irritation, resulting in inadequate adherence. 99 Permethrin 5% cream is the most effective topical treatment, 100 but is expensive and unavailable in most countries. 21 Topical treatments that are available in some low-income and middle-income countries include benzyl benzoate and sulphur ointments, but these are less well tolerated. Both options commonly cause skin irritation and stinging after application, and sulphur ointments are messy, malodourous, and require repeat treatments. 21 The effectiveness and safety profile of novel topical agents, including tea tree oil, for individual case management should be further explored. [101] [102] [103] [104] [105] [106] [107] [108] Oral medicines have clear advantages for treatment of asymptomatic individuals, and particularly for treatment of whole populations through mass drug administration (MDA), where oral medications are more likely to be accepted and ingestion can be directly observed. Oral ivermectin is highly effective against scabies. As ivermectin does not kill the scabies eggs, a second dose is usually recommended after 7-14 days to kill newly hatched mites. A recent Cochrane review did not find any difference in efficacy when one dose was compared with two doses of ivermectin, or between oral ivermectin and topical permethrin. 109 Although the strength of the review conclusions was limited by the quality of included studies, available evidence suggests that a single dose of ivermectin has some efficacy, and that two doses are likely to be similarly effective to permethrin for individual treatment. Extensive knowledge exists on the feasibility and safety of using ivermectin for MDA for other NTDs such as lymphatic filariasis and onchocerciasis. 110 An oral agent with a longer duration of activity in the skin, and which could persist for sufficient time to kill newly hatched mites, would obviate the need for a second dose and represent a major advance. Slow-release formulations of ivermectin have been developed, providing potential therapeutic effect for up to 6 months. 111 These treatments warrant further investigation for scabies, although if the dosage form is large, administration to children might be challenging. Moxidectin, a macrocyclic lactone antiparasitic agent related to ivermectin, has a halflife of up to 43 days, with prolonged activity in the skin. 112, 113 The drug is effective against Sarcoptes infestations in animals, and in a preclinical trial using a porcine model of scabies, single-dose moxidectin was shown to be superior to two doses of ivermectin on the basis of the primary outcome measure of mite score. 114 In 2018, moxidectin was approved by the US Food and Drug Administration (FDA) for treatment of onchocerciasis in individuals aged 12 years and older. 115 Clinical trials of moxidectin for scabies (eg, NCT03905265) have now commenced, with a plan to develop palatable products for children. 116 Research into scabies treatments also needs to consider safety, including treatment of pregnant and breastfeeding women and small children, groups that carry a disproportionate burden of scabies and are responsible for much of its transmission. Administration of topical treatment to these groups during ivermectinbased MDA is a major cost and logistical issue. Due to the inadequacy of existing safety data, use of ivermectin in MDA programmes for other NTDs has been restricted to individuals weighing over 15 kg or taller than 90 cm (or aged 5 years or older in some settings). However, several studies have reported no serious adverse outcomes from clinical and inadvertent public health use in young children. 117, 118 Further investigation of the safety of ivermectin in young children, and collection of prospective data on the safety of moxidectin, are priorities. Ivermectin is considered a pregnancy category C drug by the FDA, but this determination is based on animal studies that used doses far in excess of those recommended for people. 119 Studies comparing inadvertent treatment in pregnant women to controls have not shown any concerning safety signal. [120] [121] [122] [123] In other NTD programmes, ivermectin is offered when the risk of disease is considered higher than the theoretical risk to the fetus. 124 In France, ivermectin is a recommended second-line treatment for scabies during pregnancy. 125 Ivermectin is excreted in very low concentrations in human milk, and is generally regarded as safe in lactating women after the infant is 7 days old. Ivermectin can cause serious adverse events in individuals with high blood counts of Loa loa (a parasite found in central Africa) microfilariae. Development of new diagnostic technologies such as the LoaScope (University of California Berkeley, Berkeley, CA, USA) might enable safe delivery of ivermectin MDA in these areas, 126 but further investigation of implementation is needed. 127 To capitalise on existing MDA platforms for other NTDs, the safety of coadministration of ivermectin with other medications needs to be established. In addition to the long-standing practice of coadministration with albendazole, large-scale studies have now shown the safety of coadministration with azithromycin, opening the possibility of integrating control of scabies with control of yaws or trachoma. [128] [129] [130] Similarly, early analysis of a multinational safety cohort study of combination therapy of ivermectin, diethylcarbamazine, and albendazole (IDA) for lymphatic filariasis did not reveal safety concerns, and administration of this combination of drugs has now been recommended for specific epidemiological contexts within WHO guidelines. [131] [132] [133] [134] Monitoring for development of resistance of mites to acaricides will also be important. Isolated cases of resistance to ivermectin have been reported in patients with crusted scabies who received repeated and prolonged treatment. [135] [136] [137] Annual MDA might be less likely to promote the development of resistance than repeated individual treatments, but insufficient research has been done on this subject. 138 The proposed use of ivermectin MDA for malaria control 119, 139 could also promote resistance, particularly if a strategy of multiple doses each month is used. 140 However, the risk of resistance seems to be greater for intestinal helminths than ectoparasites, based on evidence from livestock, in which resistance to ivermectin among intestinal parasites is now widespread. 141, 142 Inc reasing use of topical treatments for other conditions in humans, such as permethrin for head lice and topical ivermectin for rosacea, might also promote resistance in scabies mites. 143 Detailed treatment guidelines for scabies have been developed in several high-income countries and regions, but recommendations vary. [144] [145] [146] Standardised, evidencebased treatment guidelines for resource-poor settings, including individual case management and management of outbreaks in institutions or closed communities, would be valuable. Further investigation and development of guidelines for the appropriate treatment for individuals with crusted scabies in these settings would also facilitate the success of control interventions.
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Population-level control
The strategy of individual case management has not appreciably reduced the transmission of scabies in highprevalence settings. 6, 150 Data from studies using MDA have led to renewed interest in the potential of MDA to contribute to sustained population-level control. 151, 152 Programmes of mass treatment combined with additional screening and case management in Panama and Australia (using permethrin) 6, 17, 153 and the Solomon Islands (using ivermectin) 154 considerably reduced scabies prevalence. Indirect evidence from Zanzibar, Tanzania, suggested a reduction in consultations and prescriptions for scabies following annual MDA of ivermectin and albendazole for lymphatic filariasis, 155, 156 but a study from a lower-prevalence setting in mainland Tanzania did not show a sustained effect. 157 However, in lymphatic filariasis control programmes, children aged younger than 5 years of age are not given ivermectin (or any other agent active against scabies), which might explain ongoing transmission in this context. The only controlled trial of community treatment published to date was done in small, relatively isolated island populations in Fiji, where a single round of ivermectinbased MDA reduced the prevalence of scabies by 94%, which exceeded that of the permethrin-based MDA (62% reduction) and screen-and-refer (49% reduction) groups. 158 These effects have now been shown to be sustained up to 24 months after intervention. 159 Ivermectin-based MDA also resulted in a reduction of impetigo prevalence of 67% without adjunctive mass antibiotic treatment. Further studies in the Solomon Islands using ivermectin-based MDA in a much larger population reported reductions in scabies prevalence of around 90%, and in impetigo prevalence of around 75%. 14, 130 Conversely, ivermectin-based MDA for scabies in northern Australia was not associated with a sustained reduction in prevalence. 79 The different results observed in the Australian study might have been because of increased interactions with surrounding untreated communities, lower baseline prevalence (4% compared with 32-42% in the Fiji study), 158 or transmission from untreated individuals with crusted scabies.
These studies set the scene for further investigation of the role of programmatic MDA in scabies control. Priority future studies include investigation of whether a single dose of ivermectin (as opposed to two doses, 7-14 days apart) is sufficiently effective as MDA for scabies, and investigation of ivermectin-based MDA in other settings, including non-island populations where population mobility might be greater. While existing MDA data suggest effectiveness of 10-40% in populations with high or very high prevalence, 12, 130, 158 the relative roles of MDA and case management in lower-prevalence (eg, <10%) populations have not yet been adequately explored. Investigating the effect of MDA for scabies on complications such as skin and soft tissue infection, sepsis, and autoimmune sequelae will be important, but will require a large sample size and substantial investment in infrastructure for active surveillance. Studies of moxidectin-based MDA should also be prioritised if initial individually randomised clinical trials show efficacy.
Implementation research assessing integration of scabies control with that of other NTDs, particularly those affecting the skin, could assess whether multiple health interventions can be delivered cost-efficiently. 56, 160 Initial studies could focus on understanding the effect of ivermectin-based MDA for onchocerciasis and lymphatic filariasis on the prevalence of scabies in areas that are scaling up treatment, and the effect of cessation of MDA in areas that are scaling down treatment. Concern exists that when ivermectin use in these programmes is rolled back in some countries, a resurgence of scabies infestation could occur, which might be a major unintended consequence for communities. An additional research priority will be to investigate the feasibility and effect of adding topical scabies treatment of young children to existing ivermectin-based NTD programmes. The possibility of developing a scabies vaccine has been considered, although this approach is still at an early stage of development. 43, 161, 162 Developing a global strategy Despite some deficiencies in the evidence for scabies control strategies, preliminary recommendations are needed for countries wishing to commence control measures, alongside pursuit of the research agenda described here. Initial guidance is required on the threshold of scabies prevalence above which MDA could be recommended and other health-system-related, geographical, sociopolitical, or pragmatic factors that might affect this decision. In lower-prevalence settings, intensified case management strategies might be more appropriate. If MDA is to be used on a large scale, then guidance will be required on the control target, number and frequency of MDA rounds, and monitoring and surveillance plan, including post-MDA surveillance, drawing on the lessons from other NTDs. 163 This initial guidance should draw on the existing evidence base, and-acknowledging the limitations of current dataexpert opinion and modelling studies, with plans made for guidance to be refined as further evidence becomes available. If sustained control can be shown, then the possibility of elimination (interruption of transmission) at a national or regional level might be appropriate to consider.
Once a mapping strategy is developed as part of a global control strategy, it will be possible to estimate the size of at-risk populations requiring ivermectin and permethrin within individual countries and, with less certainty, at regional and global levels. Individual countries would be able to develop control plans as part of broader NTD strategies, taking into consideration the relative burden of scabies and other health issues.
Advocating for access to affordable, quality-assured medications will be essential. Ivermectin has been generously donated for onchocerciasis and lymphatic filariasis in Africa and Latin America through the Mectizan Donation Program. This donation has enabled ivermectin use to be expanded to countries where onchocerciasis is not endemic, as part of the IDA treatment strategy for lymphatic filariasis elimination. 164 However, whether such a programme could be extended to include scabies control is unclear. Although a donation programme would maximise the likelihood of achieving control, low-cost, high-quality generic ivermectin might also be affordable in some settings. In addition to advocacy for donations, manufacturers of generic ivermectin could be supported to apply for WHO prequalification. No precedent exists for a donation programme for permethrin, and considerable amounts of the drug would be required for treatment of individuals for whom ivermectin is contraindicated. The licence holders of moxidectin, Medicines Devel opment for Global Health, have committed to providing moxidectin at an affordable price for scabies control in low-income and middleincome countries, if efficacy is shown.
116
Conclusions
Scabies is a common illness and major health issue affecting communities in many resource-poor settings, warranting public health intervention. Strong evidence suggests that ivermectin-based MDA strategies can be highly effective in reducing the burden of scabies and impetigo in some settings. Future research priorities include further defining the burden of disease, development of standardised approaches to diagnosis and population burden estimation, novel diagnostics, and treatments, and evaluation of large-scale community control strategies. Interim guidance on scabies control is now required.
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